Breaking News

Teva and Samsung Bioepis Launch EPYSQLI in the U.S.

EPYSQLI is designed to treat gMG in adults who are anti-acetylcholine receptor antibody positive.

By: Rachel Klemovitch

Assistant Editor

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Samsung Bioepis announced the availability of EPYSQLI (eculizumab-aagh) in the U.S. EPYSQLI is a biosimilar to Soliris (eculizumab) to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive.  In July 2024, the FDA approved EPYSQLI as a biosimilar to Soliris to tre...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters